Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Duffy, Danielle

< Back



Danielle Duffy, MD

Contact Dr. Duffy

925 Chestnut Street
Mezzanine Level
Philadelphia, PA 19107

(215) 955-3607
(215) 503-3976 fax

Medical School

University of Pennsylvania School of Medicine - 2002


Hospital of the University of Pennsylvania


University of Pennsylvania School of Medicine
Cardiovascular Diseases, Thomas Jefferson University Hospital

Board Certification

Internal Medicine
Cardiovascular Disease

Hospital Appointment

Thomas Jefferson University Hospital

Expertise & Research Areas

My areas of clinical expertise are complex lipid disorders, cardiovascular prevention, and cardiovascular disease in women. My general research focus is preventive cardiology. My specific interests and ongoing projects involve new therapeutics for HDL and LDL-cholesterol, the use of additional diagnostic testing for cardiovascular risk stratification, and women's cardiovascular prevention.


Lipid disorders; preventive cardiology; familial hypercholesterolemia; new therapeutics; women's cardiovascular health


Most Recent Peer-Reviewed Publications

  1. Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial
  2. Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke
  3. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry
  4. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States
  5. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice
  6. 2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk
  7. Targeting Lipoprotein (a): an Evolving Therapeutic Landscape
  8. PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers
  9. Novel treatments for familial hypercholesterolemia: Pharmacogenetics at work
  10. Aspirin for cardioprotection and strategies to improve patient adherence
  11. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia
  12. The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction
  13. Potent and selective PPAR-α agonist LY518674 upregulates both apoA-I production and catabolism in human subjects with the metabolic syndrome
  14. Update on strategies to increase hdl quantity and function
  15. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
  16. Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity
  17. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport
  18. High-density lipoprotein cholesterol therapies: The next frontier in lipid management
  19. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome
  20. Drugs in development: Targeting high-density lipoprotein metabolism and reverse cholesterol transport